Daniel Estes, Ph.D.

Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 11 years.

Dan joined Frazier Life Sciences in 2011 and focuses on venture investments in both development-stage and commercial-stage pharmaceutical companies. He has been a co-founder of multiple FLS investments including Arcutis (NASDAQ: ARQT), Lengo Therapeutics (acquired by Blueprint Medicines), Inipharm, Sudo Bio, and Iolyx, and he has helped put together multiple other companies as founding investor including Radionetics Oncology, Eyconis, and Callio Bio. He has also led Frazier’s investments in Tarsus Pharmaceuticals (NASDAQ: TARS), Sierra Oncology (acquired by GSK), Alesta Therapeutics, HIllstar Bio, and Hummingbird Bioscience.

Dan has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NASDAQ: PCVX), Translate Bio (acquired by Sanofi), and PreCision Dermatology (acquired by Valeant).

Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in Biomedical Engineering from the University of Michigan and holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.